Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries

Unniachan, Sreevalsa; Bash, Lori D.; Khovidhunkit, Weerapan; Sri, Rahmadani; Vicaldo, E.; Recto, Cesar S.; Ambegaonkar, Baishali

doi:10.1111/ijcp.12407

Cited by 7 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of raised LDL-c in our study was 21%. This rate is lower than the studies reported by Iloh et al (2012) and Unniachan et al (2014). The prevalence rate in these two studies was 23.8% and 86.2%, respectively.…”

Section: Discussioncontrasting

confidence: 67%

Factors associated with atherogenic dyslipidemia among hypertensive patients at southern Ethiopia

Hirigo¹,

Geleta²

2018

Int. J. Med. Med. Sci.

View full text Add to dashboard Cite

Atherogenic dyslipidemia worsens cardiovascular functions and supporting data concerning dyslipidemia among hypertensive patients in Ethiopian situation is very limited. The objective of this study was to assess factors associated with atherogenic dyslipidemia among hypertensive patients at Southern Ethiopia. A cross-sectional study was conducted on 238 hypertensive participants at Hawassa University comprehensive specialized hospital from September 2015 to June 2016. Systematic random sampling technique was used and written informed consent was obtained from each participant. Sociodemographic and other relevant data were collected by pre-structured questionnaires. In addition overnight fasting blood sample was collected from each study subjects for serum biochemicals determination. About 90.8% of patients had least one dyslipidemia, with the most frequent being hypertriglyceridemia (62.2%) and low high-density lipoprotein cholesterol (HDL-c, 60.9%). Being a female was significantly associated with dyslipidemia. The adjusted odds ratio (95% CI) was 2.1 (1.2-3.9; P=0.01) for hypercholesterolemia (TC), 2.4 (1.1-4.9; P=0.02) for raised low-density cholesterol (LDL-c) and 2.9 (1.6-5.4; P<0.0001) for low HDL-c. In addition, patients with hyperuricemia were more likely to develop hypercholesterolemia, hypertriglyceridemia, low HDL-c and raised TC/HDL-c when compared to patients with normouricemia. The adjusted odds ratio (95% CI) was 1.8 (1.1-3.1; P=0.047), 2.6 (1.4-4.8; P= 0.001), 2.7 (1.5-4.8; P=0.001) and 3.1 (1.7-5.4, P<0.0001), respectively. The prevalence of raised TC, LDL-c, triglycerides and low HDL-c were higher in hypertensive patients and these are an established atherogenic lipid profiles. Therefore, lipid profiles should be performed at the baseline of hypertension diagnosis prior to starting any anti-hypertensive agents and then periodically through treatment followup to manage any increasing trends.

show abstract

Section: Discussioncontrasting

confidence: 67%

Factors associated with atherogenic dyslipidemia among hypertensive patients at southern Ethiopia

Hirigo¹,

Geleta²

2018

Int. J. Med. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Numerous papers have reported the data on lipid profile and dyslipidemia prevalence in different countries and regions worldwide, indicating the real need and importance of having data on the national characteristics of these disorders, including socioeconomic, behavioral, metabolic, and hereditary peculiarities [ 13 , 14 , 15 , 16 , 17 , 18 ]. However, in most studies, only trends of means of TC, HDL-C, and non-HDL-C have been assessed, and the analysis did not include other lipids of interest to researchers and clinicians.…”

Section: Discussionmentioning

confidence: 99%

“…There are accumulating data showing that the burden of ASCVD and dyslipidemia is increasing across developing countries: while age-specific ASCVD in many high-income countries is declining, the prevalence of plasma lipid disorders in the Asia-Pacific region is rising [14,17]; similar data were reported for Mexico [19]. In a recent review, Carrillo-Larco et al demonstrated that the most common type of dyslipidemia in Latin America and the Caribbean region since 2005 is low HDL-C level (48%), followed by elevated TG (21%) and high LDL-C (20%) [21].…”

Section: Discussionmentioning

confidence: 99%

Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study

Metelskaya

Шальнова

Yarovaya

et al. 2022

IJERPH

View full text Add to dashboard Cite

This study aimed to describe the dyslipidemia prevalence and pattern among adult populations from different regions (n = 13) of the Russian Federation (RF). Randomly selected samples (n = 22,258, aged 25–64) were studied according to the ESSE-RF protocol. Lipoprotein parameters were estimated by routine methods. Statistical analyses were performed using R software (v.3.5.1). The overall dyslipidemia prevalence was 76.1% (76.9/75.3% for men/women). In women, total cholesterol (TC) and low-density lipoprotein (LDL)-C levels gradually increased with age (from 4.72 to 5.93 and from 2.76 to 3.79 mmol/L, respectively); in men, they reached a maximum by 45–54 (5.55 and 3.55 mmol/L, respectively) and then decreased. No differences in high-density lipoprotein (HDL)-C in men of different ages were found, but slight decreases in HDL-C and apo AI were observed in women by 55–64 years. No pronounced associations between education and lipid levels in men were observed; higher-educated women showed significantly better lipoprotein profiles. Similar associations between lipids and income level were detected. Women from rural areas had higher TC and triglycerides than urban residents. Regardless of sex, rural residents had higher HDL-C and apo AI, and reduced apo B/apo AI. Conclusion: Information on the peculiarities of dyslipidemia prevalence and lipoprotein profile depending on sex, age, residential place, and socioeconomic status is useful for assessing the global ASCVD risk, and for risk modeling based on national data.

show abstract

“…Studies in other countries have shown that the poor LDL-C control rate for high-risk patients treated in general practice is a global problem [31][32][33]. In South Africa, the control rate for very high-risk patients was reported to be only 26.5%.…”

Section: Treatment Aims and Low-density Lipoprotein Cholesterol (Ldl-mentioning

confidence: 99%

Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination

Han

Yang

Yin

et al. 2019

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

Elevated serum low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease (CHD). Many guidelines recommend LDL-C as a primary treatment target, and statins represent the cornerstone of treatment for lipid management. Recently revised guidelines recommend even more intense management of LDL-C, especially in patients at moderate and high risk. However, LDL-C levels in the Chinese population differ from those in Western populations, and the benefits and safety of the maximum allowable dose of statins have yet to be determined. Furthermore, in practice, many patients do not achieve the increasingly stringent LDL-C goals. Consequently, alternative approaches to lipid management are required. Combination therapy with ezetimibe and a statin, which have complementary mechanisms of action, is more effective than statin monotherapies, even at high doses. Several clinical studies have consistently shown that combination therapy with ezetimibe and simvastatin lowers LDL-C more potently than statin monotherapies. Moreover, the safety and tolerability profile of the combination therapy appears to be similar to that of low-dose statin monotherapies. This review discusses the role of simvastatin in combination with ezetimibe in controlling dyslipidemia in Chinese patients, particularly the efficacy and safety of combination therapy in light of recently published clinical data. Sheng-Na Han and Wei-Hong Yang have contributed equally to this work.

show abstract

Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries

Cited by 7 publications

References 33 publications

Factors associated with atherogenic dyslipidemia among hypertensive patients at southern Ethiopia

Factors associated with atherogenic dyslipidemia among hypertensive patients at southern Ethiopia

Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study

Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination

Contact Info

Product

Resources

About